Instructions for Pantestin-Darnitsa gel tube 15 g
Composition
active ingredients: dexpanthenol, myramistin;
1 g of gel contains: dexpanthenol (D-panthenol) 50 mg, miramistin 5 mg;
excipients: propylene glycol, polyethylene glycol (macrogol 400), poloxamer, cetyl alcohol, stearyl alcohol, purified water.
Dosage form
Gel.
Main physicochemical properties: homogeneous white gel with a faint specific odor.
Pharmacotherapeutic group
Medicinal products that promote wound healing (scarring). ATX code D03A X.
Pharmacological properties
Pharmacodynamics
The active substance of the drug Pantestin-Darnitsa® dexpanthenol is a provitamin. When applied to the skin, dexpanthenol penetrates into epithelial cells and is transformed into pantothenic acid, which is a component of coenzyme A, which participates in the processes of synthesis of plastic material. This enhances the processes of formation and regeneration of the skin, wounds that are difficult to heal, complicated wounds.
Since wounds that are difficult to heal are usually complicated by wound infection, in order to prevent and treat wound infection, a cationic antiseptic, Miramistin, has been introduced into the drug, the antimicrobial effect of which complements the effect of dexpanthenol.
Pharmacokinetics
Dexpanthenol is metabolized in the tissues at the site of application. It practically does not penetrate into the systemic bloodstream.
Miramistin, due to the properties of the polymeric substances of the ointment base, remains on the wound surface and is not absorbed into the systemic bloodstream.
Indication
Surgery: treatment of wounds of various localization and genesis, including postoperative wounds, trophic ulcers and bedsores in the regeneration phase (phase II of the wound process). Combustiology: treatment of granulating burn wounds, their preparation for autodermoplasty, improvement of skin graft adhesion after plastic surgery, treatment of sunburn. Radiation medicine: prevention of radiation damage to mucous membranes, skin and surrounding tissues, treatment of radiation ulcers in the regeneration phase. Dentistry: treatment of periodontal diseases (catarrhal, ulcerative-necrotic gingivitis, localized periodontitis, generalized periodontitis), treatment of diseases of the oral mucosa (stomatitis, chronic recurrent aphthous stomatitis), traumatic lesions of the oral mucosa (prosthetic stomatitis). Pediatrics: diaper rash and diaper dermatitis, prevention of their infection. Treatment of skin infections, in particular, secondarily infected eczema and neurodermatitis. Treatment of minor abrasions, cuts, scratches, burns and prevention of their infection in case of household injuries.
Contraindication
Hypersensitivity to the active substances or to other components of the medicinal product.
Dexpanthenol is contraindicated for use on wounds in patients with hemophilia due to the high risk of bleeding.
Interaction with other medicinal products and other types of interactions
When using the drug simultaneously with other drugs, the following are possible:
with anionic substances (soap solutions) – inactivation of the antimicrobial effect of Miramistin. Simultaneous use should be avoided; with systemic or local antibiotics – reduction of resistance of microorganisms to antibiotics; with depolarizing muscle relaxants (suxametonium chloride, decamethonium bromide) – increased effectiveness of the latter; with non-depolarizing muscle relaxants – weakening of the effectiveness of the latter, due to the ability to stimulate the synthesis of acetylcholine.
The drug cannot be used together with other antiseptics that inactivate the antimicrobial effect of Miramistin.
Application features
Avoid contact with the eyes. If the medicine gets into the eyes, rinse them with water.
Large, heavily contaminated and deep wounds, as well as wounds resulting from bites and punctures, require medical intervention (there is a risk of tetanus). If the wound size remains large within 10-14 days or the wound does not heal, the appropriateness of prescribing the drug should be reconsidered. This is also necessary if there is severe perifocal hyperemia, the wound swells, severe pain appears, exudation increases or the injury is accompanied by fever (risk of sepsis).
The drug is not recommended for use in phase I of the wound process with pronounced purulent exudation.
If symptoms persist or worsen, you should consult a doctor.
The medicine should not be used with other medicines without first consulting a doctor.
Please note that this medicine contains propylene glycol, stearyl and cetyl alcohols - when used externally, these excipients may cause skin irritation and local skin reactions (e.g. contact dermatitis).
Ability to influence reaction speed when driving vehicles or other mechanisms
The drug does not affect the reaction speed when driving vehicles or other mechanisms.
Use during pregnancy or breastfeeding
The medicine should be used during pregnancy or breastfeeding as prescribed by a doctor, but its use on large areas should be avoided.
Method of administration and doses
The drug is applied topically. After standard wound surface treatment, the gel is applied in a thin layer to the wound, then a sterile gauze dressing is applied. If necessary, the drug can be applied to the dressing and then to the wound.
If there is exudate, before applying the drug, the wound should be washed with a solution of furatsilin (1: 5000) or hydrogen peroxide (3%) and dried with a gauze napkin.
For dermatological diseases and sunburns: the gel can be applied directly to the affected surface 2-3 times a day.
For gynecological diseases (cervical erosion, erosive colpitis): tampons impregnated with the drug can be inserted deep into the vagina in the supine position.
For dental diseases: the drug can only be used by adults locally in the oral cavity. After individual hygiene procedures, rinse the oral cavity, apply the gel in a thin layer to the surface of the gums or the affected area of the oral mucosa. Do not drink or eat for an hour. In the treatment of traumatic lesions of the oral mucosa (prosthetic stomatitis), dentures can be used after applying the gel to the affected area. The drug is used 2−3 times a day. The duration of treatment is 7−10 days, until the lesion is completely healed or the inflammatory processes decrease.
Children
The drug can be used in pediatric practice (when clinical signs of skin damage appear - from the first days of life). The duration of treatment is determined by the doctor individually. For children under 1 year of age, the drug is used with each diaper change until the clinical signs of skin damage disappear.
Overdose
With topical application, overdose is unlikely, since the active components of the drug practically do not enter the systemic bloodstream.
In case of accidental internal use of the drug, toxic effects are not expected. In case of gastrointestinal disorders, symptomatic therapy is indicated.
Adverse reactions
On the part of the immune system: in case of individual intolerance to the drug, hypersensitivity reactions are possible, which are usually manifested by changes in the skin. This is accompanied by the appearance of itching, hyperemia, local or generalized rashes, varying in clinical manifestations and severity. In some cases, local skin irritation is possible, accompanied by a burning sensation, which disappears on its own after 15-20 seconds and does not require discontinuation of the drug.
Skin and subcutaneous tissue disorders: contact dermatitis, allergic dermatitis, erythema, eczema, urticaria, skin irritation, skin swelling, blisters, dry skin, weeping.
If any adverse reactions occur, you should stop using the medicine and consult a doctor.
Expiration date
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Do not freeze. Keep out of the reach of children.
Packaging
15 g in a tube; 1 tube in a pack.
Vacation category
Without a prescription.
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
